Hereditary angioedema (HAE) is a genetic disorder which is characterized by inflammation of body organs such as limbs, face, upper airway, abdomen, etc. Level of functional C1 esterase inhibitor is decreased due to mutations in its coding gene. This leads to increased level of bradykinin in blood which results into leakage of blood vessels. Leakage of fluids into surrounding organs lead to inflammation. HAE is a rare disease, and is estimated to affect 1 in 30,000 to 1 in 50,000 across the globe. Prophylactic and acute attack treatments are offered in management of HAE.
Owing to rarity of the disease, there is lack of awareness among patients and physicians which has resulted into unmet diagnosis of the disease and in turn mismanagement of the disease. HAE is often misdiagnosed to common allergies and abdominal pain. However this scenario is changing in developed markets such as the U.S. and Western Europe. With increasing awareness about the disease and introduction of novel drugs for treatment, global hereditary angioedema market is projected to grow during the forecast period. Owing to rarity of HAE, its specialty drugs has received orphan drug designation across the markets they are offered. This gives them formal incentives such as regulatory process fee reduction, tax benefits, market exclusivity, etc. These factors are projected to drive growth for this segment. However these medicines attract high cost, which distracts many patients to rely on conventional HAE drugs, restraining growth for global hereditary angioedema market.
Based on the drug class, global Hereditary Angioedema Market is segmented into C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, Kallikrein inhibitor and others. The C1 esterase inhibitor segment is further classified into Cinryze, Berinert and Ruconest, as these are the only approved C1 esterase inhibitor drugs for treatment of HAE. Berinert with its strong presence in Europe and Rest of the World market is anticipated to have prominent growth during the forecast period from 2017 to 2025. Expiry of orphan drug market exclusivity of these products is anticipated to hamper the growth of this segment, however projected launch of their subcutaneous variants and their label extension is estimated to compensate this downfall. C1 esterase inhibitor segment is likely to register growth at CAGR of 4.3% from 2017 to 2025. Firazyr is the only approved selective bradykinin B2 receptor antagonist, owing to its better efficacy in acute attack treatment of HAE it is projected to expand at CAGR of 1.5% from 2017 to 2025. The others segment is classified into conventional drugs such as attenuated androgens and pipeline drugs such as DX-2930 and BCX-7353. Owing to rise in preference for prophylactic treatment of HAE and promising trail outcomes of pipeline drugs the others segment is projected to witness an exponential growth during the forecast period from 2017 to 2025.
By route of administration, the global hereditary angioedema market is segmented into intravenous subcutaneous injection and oral. Increasing preference for self-administrable drugs is estimated to increase the market share for subcutaneous injectable and orally administrable HAE drugs. Projected launch of subcutaneous variants of Cinryze, Berinert and pipeline drug DX-2930 is estimated to drive propel growth for subcutaneous injection segment. This segment is projected to expand at CAGR of 15.5% from 2017 to 2025. Based on distribution channel, the global hereditary angioedema market is segmented into hospital pharmacies, retail pharmacies and others. On emergence of HAE attacks, the patients need to be hospitalized, the symptoms of the attack lasts for 24 to 48 hours and subsequently fade away. This factor has contributed for prominent share of hospital pharmacies in global hereditary angioedema market. With rise in preference of prophylactic treatment of HAE and industry’s efforts in strengthening of distribution network across regions is estimated to boost growth for retail pharmacies segment. This segment is estimated to expand at CAGR of 9.4% from 2017 to 2025.
Geographically the global hereditary angioedema market is segmented in to North America, Europe and Rest of the World. North America region dominated the global hereditary angioedema market and is projected to expand at CAGR of 8.3 % over forecast period from 2017 to 2025. High healthcare expenditure from public & private sector for treatment of HAE and availability of specialty drugs in this region is projected to contribute for dominating share of North America in global hereditary angioedema market. Europe hereditary angioedema market is estimated to grow at CAGR of 10.8% from 2017 to 2025. Emerging markets such as India, China, Brazil and well established market such as Japan and Australia, the Rest of World hereditary angioedema market is estimated to grow at CAG of 13.5% during the forecast period from 2017 to 2025.
Get more Information – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17135